Drug Profile
Azithromycin - Pfizer
Alternative Names: Sumamed; Z-PAK; Zithromax; Zithromax IV; Zytromax EVLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator PLIVA d.d.
- Developer Cystic Fibrosis Foundation; Pfizer; St. Michaels Hospital; University of Oxford; University of Wisconsin-Madison
- Class Anti-inflammatories; Antibacterials; Antivirals; Eye disorder therapies; Macrolides; Small molecules
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Otitis media; Pelvic inflammatory disorders; Sexually transmitted infections
- Phase II COVID 2019 infections
- No development reported Asthma; Cholera; Cystic fibrosis-associated respiratory tract infections; Gastroparesis; Pertussis; Typhoid
- Discontinued Acute coronary syndromes
Most Recent Events
- 26 Sep 2022 Azithromycin is still in the phase II ATOMIC2 trial for COVID-2019 infections (In adults, In the elderly) in UK (PO) (NCT04381962) (EudraCT2020-001740-26)
- 20 Apr 2021 University of Oxford in collaboration with Pfizer completes the phase II ATOMIC2 trial for COVID-2019 infections (In adults, In the elderly) in UK (PO) (NCT04381962) (EudraCT2020-001740-26)
- 03 Jun 2020 Phase-II clinical trials in COVID-2019 infections (In adults, In the elderly) in United Kingdom (PO) (NCT04381962) (EudraCT2020-001740-26)